217 related articles for article (PubMed ID: 20831911)
1. Combined peptides of human enterovirus 71 protect against virus infection in mice.
Liu JN; Wang W; Duo JY; Hao Y; Ma CM; Li WB; Lin SZ; Gao XZ; Liu XL; Xu YF; Xu WB; Qin C; Zhang LF
Vaccine; 2010 Oct; 28(46):7444-51. PubMed ID: 20831911
[TBL] [Abstract][Full Text] [Related]
2. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71.
Mao Q; Li N; Yu X; Yao X; Li F; Lu F; Zhuang H; Liang Z; Wang J
Arch Virol; 2012 Jan; 157(1):37-41. PubMed ID: 21984267
[TBL] [Abstract][Full Text] [Related]
3. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides.
Li X; Mao C; Ma S; Wang X; Sun Z; Yi Y; Guo M; Shen X; Sun L; Bi S
Biochem Biophys Res Commun; 2009 Dec; 390(4):1126-8. PubMed ID: 19799860
[TBL] [Abstract][Full Text] [Related]
4. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection.
Chen HL; Huang JY; Chu TW; Tsai TC; Hung CM; Lin CC; Liu FC; Wang LC; Chen YJ; Lin MF; Chen CM
Vaccine; 2008 Jun; 26(23):2882-9. PubMed ID: 18450335
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
6. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge.
Chung YC; Ho MS; Wu JC; Chen WJ; Huang JH; Chou ST; Hu YC
Vaccine; 2008 Mar; 26(15):1855-62. PubMed ID: 18329759
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of enterovirus‑71 (EV71) virus‑like particle vaccine against lethal EV71 infection in a neonatal mouse model.
Cao L; Mao F; Pang Z; Yi Y; Qiu F; Tian R; Meng Q; Jia Z; Bi S
Mol Med Rep; 2015 Aug; 12(2):2473-80. PubMed ID: 25936344
[TBL] [Abstract][Full Text] [Related]
8. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice.
Ku Z; Liu Q; Ye X; Cai Y; Wang X; Shi J; Li D; Jin X; An W; Huang Z
Vaccine; 2014 Jul; 32(34):4296-303. PubMed ID: 24950363
[TBL] [Abstract][Full Text] [Related]
9. Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant Newcastle disease virus capsids displaying the EV71 VP1 fragment.
Ch'ng WC; Stanbridge EJ; Ong KC; Wong KT; Yusoff K; Shafee N
J Med Virol; 2011 Oct; 83(10):1783-91. PubMed ID: 21837796
[TBL] [Abstract][Full Text] [Related]
10. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection.
Bek EJ; Hussain KM; Phuektes P; Kok CC; Gao Q; Cai F; Gao Z; McMinn PC
Vaccine; 2011 Jun; 29(29-30):4829-38. PubMed ID: 21550375
[TBL] [Abstract][Full Text] [Related]
11. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice.
Wu TC; Wang YF; Lee YP; Wang JR; Liu CC; Wang SM; Lei HY; Su IJ; Yu CK
J Virol; 2007 Oct; 81(19):10310-5. PubMed ID: 17626076
[TBL] [Abstract][Full Text] [Related]
12. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine.
Chen CW; Lee YP; Wang YF; Yu CK
Vaccine; 2011 Mar; 29(15):2772-6. PubMed ID: 21315698
[TBL] [Abstract][Full Text] [Related]
13. Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71.
Wang X; Dong K; Long M; Lin F; Gao Z; Wang L; Zhang Z; Chen X; Dai Y; Wang H; Zhang H
Arch Virol; 2018 Jul; 163(7):1851-1861. PubMed ID: 29582164
[TBL] [Abstract][Full Text] [Related]
14. Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections.
Liu J; Zhao B; Xue L; Wu J; Xu Y; Liu Y; Qin C
Virol J; 2020 Apr; 17(1):58. PubMed ID: 32321526
[TBL] [Abstract][Full Text] [Related]
15. Establishment of an animal challenge model as a potency assay for an inactivated Enterovirus Type 71 vaccine.
Wang KT; Lin SJ; Wang HC; Chen PC; Lin JJ; Chiang JR; Chang CL; Shih DY; Lo CF; Wang DY
Biologicals; 2016 Jul; 44(4):183-190. PubMed ID: 27068365
[TBL] [Abstract][Full Text] [Related]
16. Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.
Wang X; Ku Z; Zhang X; Ye X; Chen J; Liu Q; Zhang W; Zhang C; Fu Z; Jin X; Cong Y; Huang Z
J Virol; 2018 Jan; 92(1):. PubMed ID: 29070691
[TBL] [Abstract][Full Text] [Related]
17. Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice.
Wang M; Jiang S; Wang Y
Biochem Biophys Res Commun; 2013 Jan; 430(1):387-93. PubMed ID: 23159634
[TBL] [Abstract][Full Text] [Related]
18. EV71: an emerging infectious disease vaccine target in the Far East?
Xu J; Qian Y; Wang S; Serrano JM; Li W; Huang Z; Lu S
Vaccine; 2010 Apr; 28(20):3516-21. PubMed ID: 20304038
[TBL] [Abstract][Full Text] [Related]
19. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.
Jiang L; Fan R; Sun S; Fan P; Su W; Zhou Y; Gao F; Xu F; Kong W; Jiang C
Vaccine; 2015 Nov; 33(48):6596-603. PubMed ID: 26529072
[TBL] [Abstract][Full Text] [Related]
20. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.
Liu CC; Chow YH; Chong P; Klein M
Vaccine; 2014 Oct; 32(47):6177-82. PubMed ID: 25218294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
